Vioxx probe underway in the U.K
Executive Summary
The U.K. Medicines & Healthcare products Regulatory Agency announced Aug. 24 that it is investigating Merck's compliance with pharmacovigilance requirements for Vioxx. Merck could be subject to fines and employees could face two years imprisonment for failing to provide the agency with information relevant to its evaluation of the risks and benefits of the product...